Concord Biotech Ltd

Concord Biotech Ltd

₹ 1,443 4.04%
21 Feb - close price
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Busines segments
A) APIs[1] Co manufactures API's through fermentation and semi-synthetic processes, across therapeutic areas of immunosuppressants, oncology, and anti-infectives
B) Formulations[2] which are used in therapeutic areas of immunosuppressants, nephrology and anti-infective drugs for critical care.

  • Market Cap 15,121 Cr.
  • Current Price 1,443
  • High / Low 1,608 / 900
  • Stock P/E 50.2
  • Book Value 129
  • Dividend Yield 0.00 %
  • ROCE 26.2 %
  • ROE 19.6 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 11.2 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
181 159 241 273 195 262 241
116 121 129 144 123 143 135
Operating Profit 65 38 112 129 72 119 106
OPM % 36% 24% 46% 47% 37% 45% 44%
8 6 9 12 7 8 8
Interest 1 1 1 1 1 1 0
Depreciation 14 13 14 14 13 13 14
Profit before tax 58 30 106 126 65 113 100
Tax % 26% 26% 26% 26% 25% 25% 26%
43 22 79 94 48 84 75
EPS in Rs 45.32 2.14 7.56 8.94 4.63 8.08 7.13
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
340 436 512 617 713 853 971
195 256 308 289 439 504 544
Operating Profit 145 180 205 328 274 349 426
OPM % 43% 41% 40% 53% 38% 41% 44%
18 17 31 14 23 35 35
Interest 1 1 1 1 6 10 4
Depreciation 18 19 21 28 50 54 54
Profit before tax 144 178 213 313 241 320 404
Tax % 30% 33% 21% 25% 26% 26%
100 118 169 235 179 238 301
EPS in Rs 105.66 124.48 177.65 247.44 187.76 22.76 28.78
Dividend Payout % 0% 21% 22% 0% 3% 30%
Compounded Sales Growth
10 Years: %
5 Years: 20%
3 Years: 19%
TTM: 20%
Compounded Profit Growth
10 Years: %
5 Years: 19%
3 Years: 16%
TTM: 35%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 20%
3 Years: 20%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 10 10 10 10 10 10 10
Reserves 585 673 761 990 1,098 1,282 1,343
22 9 52 89 62 32 23
69 72 118 94 144 191 174
Total Liabilities 685 763 941 1,183 1,313 1,515 1,550
189 230 240 546 573 593 590
CWIP 3 19 141 18 74 173 188
Investments 151 229 199 142 74 138 151
343 285 361 477 592 611 621
Total Assets 685 763 941 1,183 1,313 1,515 1,550

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
79 155 167 207 246
-42 -114 -195 -112 -158
-37 -43 31 -100 -85
Net Cash Flow 0 -1 3 -4 3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 236 133 131 105 119 117
Inventory Days 381 310 312 503 434 430
Days Payable 210 112 201 152 185 190
Cash Conversion Cycle 407 331 242 456 368 357
Working Capital Days 275 186 160 196 179 163
ROCE % 27% 25% 32% 21% 26%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2023Dec 2023
44.08% 44.08%
7.30% 7.00%
8.12% 8.40%
40.50% 40.52%
No. of Shareholders 1,00,92787,486

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Annual reports

No data available.

Concalls